<\/p>\n
Roliten<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 tolterodine tartrate<\/strong> — a competitive muscarinic acetylcholine receptor antagonist used to treat overactive bladder (OAB)<\/strong> with urgency, frequency, and urge incontinence. Available as 1 mg immediate-release tablets. Standard dose: 2 mg twice daily<\/strong> (or 1 mg twice daily in renal\/hepatic impairment or with strong CYP3A4 inhibitors). For convenient once-daily dosing with smoother side-effect profile, see the extended-release formulation (Terol LA)<\/a>. Tolterodine is generally better tolerated than oxybutynin<\/strong> — less dry mouth, less constipation, and lower CNS penetration. Use with caution in adults aged 65+<\/strong> — the 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults due to cumulative anticholinergic burden. Mirabegron (Mirago)<\/strong> is the preferred first-line OAB drug in this population.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n <\/p>\n \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03c4\u03af\u03b4\u03b1 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/strong>. \u039f\u03b9 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b5\u03c2 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03ac, \u03b1\u03c3\u03ae\u03bc\u03b1\u03bd\u03c4\u03b1 \u03c0\u03b1\u03ba\u03ad\u03c4\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03bd\u03b5\u03c1\u03b3\u03ac\u03c4\u03b5\u03c2 \u03bc\u03b1\u03c2 \u03c3\u03c4\u03b7\u03bd \u03b5\u03ba\u03c0\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u03ba\u03b1\u03b9 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>: \u03b5\u03ac\u03bd \u03ad\u03bd\u03b1 \u03b4\u03ad\u03bc\u03b1 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c3\u03c4\u03ad\u03bb\u03bd\u03bf\u03c5\u03bc\u03b5 \u03bc\u03b9\u03b1 \u03b4\u03c9\u03c1\u03b5\u03ac\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2.<\/p>\n Roliten is a brand of tolterodine tartrate 1 mg immediate-release tablets<\/strong>. Tolterodine is one of the most-prescribed antimuscarinic OAB drugs worldwide. Internationally branded as Detrol \/ Detrol LA (US), Detrusitol \/ Detrusitol XL (UK \/ EU)<\/strong>. Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets\/capsules.<\/p>\n Tolterodine is a competitive antagonist at M2 and M3 muscarinic acetylcholine receptors<\/strong>. Bladder M3 blockade reduces parasympathetic-driven detrusor contractions during the filling phase — decreasing urgency and incontinence episodes and increasing functional bladder capacity.<\/p>\n Compared to oxybutynin<\/a>, tolterodine has somewhat better selectivity for bladder vs salivary-gland muscarinic receptors, lower CNS penetration, and a more favourable side-effect profile — particularly less severe dry mouth. Both are still anticholinergics with the standard class warnings about elderly use.<\/p>\n Tolterodine is metabolised by CYP2D6 to an active metabolite (5-hydroxymethyl tolterodine) which contributes substantially to clinical effect. About 5-10% of the population are CYP2D6 “poor metabolisers” who form less of the metabolite and need dose adjustment.<\/p>\n Tolterodine has somewhat lower CNS penetration than oxybutynin and is generally considered the better-tolerated of the two anticholinergic OAB drugs in older adults — but it is still classified as “potentially inappropriate” in the Beers Criteria and should be used cautiously and at the lowest effective dose. Mirabegron remains the preferred first-line OAB drug in adults aged 65+<\/strong> when affordable and not contraindicated by hypertension.<\/p>\n Do not take tolterodine if you have:<\/strong><\/p>\n \u03a7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03c4\u03b5 \u03bc\u03b5 \u03c0\u03c1\u03bf\u03c3\u03bf\u03c7\u03ae \u03b5\u03ac\u03bd \u03ad\u03c7\u03b5\u03c4\u03b5:<\/strong> elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, congenital or acquired QT prolongation, coronary artery disease.<\/p>\n\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
\n
What is Roliten?<\/h2>\n
How tolterodine works<\/h2>\n
When tolterodine is used<\/h2>\n
\n
\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 & \u03c4\u03c1\u03cc\u03c0\u03bf\u03c2 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2<\/h2>\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2 & \u03b1\u03c3\u03c6\u03ac\u03bb\u03b5\u03b9\u03b1<\/h2>\n
\n
Anticholinergic burden & the elderly<\/h2>\n
\u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 & \u03c0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n
\n
How tolterodine compares<\/h2>\n